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Abstract
Background: Asthma comorbidity has been correlated with poor asthma control, increased health services use, and
decreased quality of life. Managing it improves these outcomes. Little is known about the amount of different types of
comorbidity associated with asthma and how they vary by age.
Methodology/Principal Findings: The authors conducted a population study using health administrative data on all
individuals living in Ontario, Canada (population 12 million). Types of asthma comorbidity were quantified by comparing
physician health care claims between individuals with and without asthma in each of 14 major disease categories; results
were adjusted for demographic factors and other comorbidity and stratified by age. Compared to those without asthma,
individuals with asthma had higher rates of comorbidity in most major disease categories. Most notably, they had about
fifty percent or more physician health care claims for respiratory disease (other than asthma) in all age groups; psychiatric
disorders in individuals age four and under and age 18 to 44; perinatal disorders in individuals 17 years and under, and
metabolic and immunity, and hematologic disorders in children four years and under.
Conclusion/Significance: Asthma appears to be associated with significant rates of various types of comorbidity that vary
according to age. These results can be used to develop strategies to recognize and address asthma comorbidity to improve
the overall health of individuals with asthma.
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Introduction
Asthma has been associated with various types of comorbidity,
from coronary artery to psychiatric disease, that place significant
burden on patients [1–3]. Asthma comorbidity has been correlated
with poor asthma control, increased health care use, and
decreased quality of life, and managing it has been shown to
significantly improve these outcomes [4–9]. Despite this, there is
still little known and relatively little attention paid to diagnosing
and treating asthma comorbidity [10]. This is in contrast to other
chronic disease comorbidity–such as renal disease among individ-
uals with diabetes and hypercholesterolemia among individuals
with coronary artery disease–that have been well studied and are
routinely identified and treated accordingly.
Knowledge of the full spectrum of diseases that accompany
asthma, the diseases that have the greatest impact and, as asthma
can last a lifetime, how they vary by age would help physicians,
other health care providers, and policy makers develop strategies
to recognize, prioritize, and manage asthma comorbidity effec-
tively. To the best of our knowledge, no previous studies have
systematically investigated and measured the impact of different
types of comorbidity on individuals with asthma in different life
stages. Therefore, we conducted the current study to characterize
and quantify different types of asthma comorbidity in individuals
of different ages.
Methods
Ethics Statement
The study was approved by the institutional review boards at
Sunnybrook Health Sciences Centre and The Hospital for Sick
Children, Toronto, Ontario. For the purposes of this research
informed consent was not required. The Institute for Clinical
Evaluative Sciences (ICES) is named as a prescribed entity in
Section 45 of the Personal Health Information Protection Act (PHIPA –
Regulation 329/04, Section 18). Under this designation, ICES
can receive and use health information without consent for
purposes of analysis and compiling statistical information about
the Ontario health care system.
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We conducted a retrospective population study using universal,
health administrative data from Ontario, Canada–the largest
province of Canada with a multicultural population of approxi-
mately 12 million [11].
Data Sources
Residents of Ontario have universal public health insurance
under the Ontario Health Insurance Plan, the single payer for all
medically necessary services across the full spectrum of residents,
providers and hospitals. Service details are captured in health
administrative databases which can be linked on an individual
level to provide a complete health services profile for each resident.
Three Ontario population-based health administrative databases
were used to identify individuals with asthma and measure their
comorbidity through their health services use. The Ontario Health
Insurance Plan physician services claims database contains
information about all services provided by fee-for-service physi-
cians and ‘‘shadow-billings’’ for physicians paid under alternate
payment plans. Each physician claim is accompanied by one
International Classification of Disease 9
th Revision (ICD-9)
diagnostic code. The Canadian Institute for Health Information
Discharge Abstract Database contains information on all hospi-
talizations in the province. Finally, the Ontario Registered Persons
Database maintains demographic information on all individuals
living in Ontario.
Study Population
All individuals living in Ontario on April 1, 2003 (the index
date) were followed until March 31, 2008. Those who died or left
the province were excluded. Individuals with asthma were
identified using a previously validated asthma case definition
based on health administrative data [12]. The case-definition of
two or more asthma physician visits within two consecutive years
and/or one or more asthma hospitalization yielded 89% sensitiv-
ity and 72% specificity in children (aged less than17 years) and
84% sensitivity and 76% specificity in adults (aged 18 years or
over) when compared to clinical evaluation. More details of the
asthma case definition and examples of its use in other studies can
be found elsewhere [12–14]. Subjects were stratified by age into
the following groups: less than four years (preschool), five to
17 years (children and adolescence), 18 to 44 years (younger
adults), 45 to 64 years (middle aged adults) and 65 years and older
(older adults).
Outcome Variables
The primary outcome was amount of comorbidity in individuals
with asthma which was compared to amount of comorbidity in
those without asthma. As a direct correlation between amount of
comorbidity and health service claims has been previously well
validated, amount of comorbidity was examined through physi-
cian claims [15,16]. Physician claims capture health service use in
the ambulatory, emergency department and hospitalization
setting. Comorbidity was stratified by diagnosis according to 14
ICD-9 disease categories [17]. ICD-9 categories that were vague
and/or heterogeneous (such as symptoms, signs and ill-defined
conditions and supplementary classification) were not examined.
In secondary analysis, a number of specific conditions previously
shown to be associated with asthma were also examined [1].
Details of the 14 ICD-9 disease categories and specific conditions,
their associated ICD-9 codes, and the populations in which they
were studied are presented in Supplemental Table S1.
Potential Confounding Variables
A number of demographic and clinical variables obtained from
the health administrative data were adjusted for in multivariable
analysis (Table 1). Socioeconomic status was inferred from
neighborhood income derived from postal codes and census data
[7,18]. Rural status was based on Statistics Canada’s definition of
rurality [19]. Because it could potentially be misclassified as
asthma, a co-diagnosis of chronic obstructive pulmonary disease
(COPD) was also derived from health administrative data and
controlled for [20]. Adjustment for other comorbidity as indicated
by ICD-9 category was also done.
Statistical Analyses
Frequencies and proportions were used to report socio-
demographic characteristics. Normal approximation (z) tests for
equivalence were conducted to determine if groups were
statistically equivalent, using a difference margin of two percent
absolute difference (i.e. significant p-values (p,0.05) indicated that
the true difference in proportions was less than +/2 2%). For each
Table 1. Characteristics of individuals with and without asthma living in Ontario, Canada.
Characteristic Individuals with asthma Individuals without asthma P-value for equivalence*
N 1,477,575 10,143,134
Age, years (mean (standard deviation)) 31.8 (22.8) 38.2 (21.6) 1.000
Female (%) 53.2 50.6 0.985
Socioeconomic Status
- Quintile 1 (Lowest) 19.7 18.9 ,0.001
- Quintile 2 19.9 19.7
- Quintile 3 20.2 20.1
- Quintile 4 20.4 20.5
- Quintile 5 (Highest) 19.5 20.4
Rural (versus urban) residence (%) 11.8 13.2 ,0.001
COPD (%) 16.0 4.7 1.000
COPD, Chronic Obstructive Pulmonary Disease.
*Equivalence tests performed. Significant P-values indicate that distributions are ‘practically equivalent’ to within +/2 two percentage points for proportions and
0.75 years for age.
doi:10.1371/journal.pone.0034967.t001
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e34967ICD-9 disease category and condition studied absolute counts of
physician claims and crude physician claim rates (per 1000 per-
son years) were calculated for individuals with and without
asthma. Absolute differences and their gamma-based 95%
confidence intervals were also calculated. Adjusted relative risks
of comorbidity in individuals with compared to those without
asthma (and their 95% confidence intervals) were calculated using
multivariable Poisson regression adjusting for age, sex, socioeco-
nomic status, rural/urban place of residence, a co-diagnosis of
COPD, and other comorbidity as indicated by ICD-9 categories.
An adjusted relative risk more than or equal to one indicated that
physician claims for a comorbidity were more common in
Figure 1. Adjusted relative risks and 95% confidence intervals of comorbidity, as indicated by health services use, among
individuals four years and younger and five to 17 years with compared to without asthma in 14 disease categories. Solid diamonds
represent relative risks for individuals four years and younger; hollow diamonds represent relative risks for individuals five to 17 years. All analyses
were adjusted for age, sex, socioeconomic status, rural/urban place of residence, a co-diagnosis of COPD, and other comorbidity as indicated by ICD-
9 category. * Relative risk for conditions originating in the perinatal period among individuals zero to four years old: 5.03, 95% CI: 2.08 to 12.21 and
among individuals five to 17 years old: 3.46 (2.23 to 5.36).
doi:10.1371/journal.pone.0034967.g001
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e34967individuals with compared to those without asthma and a relative
risk less than one indicated the opposite. All analyses were
stratified by age group and conducted with SAS version 9.2 for
UNIX systems (Cary, North Carolina).
Sensitivity Analysis
To assess whether it was plausible that misclassification of
asthma due to less than perfect specificity of the case definition
was responsible for the observed results, an array approach was
used [21]. The inclusion of misclassified people could have
potentially led to incorrect results if the misclassified people were
healthier (or less healthy) than those correctly identified.
Therefore, to determine if this influenced the results, we
estimated the true relative risks when different assumptions about
the health of those who were misclassified relative to those who
truly had asthma were made. We were specifically Interested in
what assumptions caused the relative risks to be reduced to 1.0 (or
no increased risk).
Figure 2. Adjusted relative risks and 95% confidence intervals of comorbidity, as indicated by health services use, among
individuals age 18 to 44 years, 45 to 64 years and 65 years and older with compared to without asthma in 14 disease categories.
Solid black circles represent relative risks for individuals 18 to 44 years; solid grey circles represent relative risks for individuals 45 to 64 years; hollow
circles represent relative risks for individuals age 65 years and older. All analyses were adjusted for age, sex, socioeconomic status, rural/urban place
of residence, a co-diagnosis of COPD, and other comorbidity as indicated by ICD-9 category.
doi:10.1371/journal.pone.0034967.g002
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e34967Results
Study Population
There were 11,903,512 individuals living in Ontario in 2003
who were followed for five years. After excluding 282,803 who
met at least one exclusion criterion (i.e. developed asthma, left the
province, or died in the follow-up period) a study population of
1,477,575 (12.7%) individuals with and 10,143,134 (86.3%)
individuals without asthma remained.
On average, individuals with asthma were younger (32 years
compared to 38 years), more likely to be female, and more likely to
have a co-diagnosis of COPD than those without asthma (Table 1).
However, when examined by age group, compared to those
without asthma, younger individuals (ages zero to four and five to
17 years) with asthma were more likely to be male and live in an
urban region; individuals in the three older age groups (18 to 44,
45 to 64 and 65 years and older) with asthma were more likely to
be female and have a co-diagnosis of COPD; and individuals in
the two oldest age groups with asthma were more likely to live in a
lower income neighborhood (data not shown).
Comorbidity in 14 Disease Categories
Compared to those without asthma, individuals with asthma
had higher rates of comorbidity, as indicated by physician claims,
in all 14 ICD-9 disease categories (Tables 2 and 3).
After adjusting for potential confounders, comorbidity in
children four years and younger was 46% higher in those with
compared to those without asthma (p,0.001; Figure 1). Higher
comorbidity was found for most of the 14 disease categories but
was highest (50% or greater) for respiratory disease (other than
asthma); psychiatric disorders; metabolic and immunity disorders;
hematologic disorders; and perinatal disorders (p,0.001 for each
disease category).
Similarly, comorbidity was 40% higher among children aged
five to 17 years with compared to without asthma (p,0.001;
Figure 1). Significantly higher physician claim rates were found in
all 14 disease categories (p,0.05) but were highest (more than
50% higher) for respiratory disease other than asthma and
perinatal disorders.
Among those aged 18 to 44 and 45 to 64 years of age,
comorbidity was 47% and 49% higher among those with
compared to those without asthma (p,0.001; Figure 2). Among
those aged 18 to 44 and 45 to 64 years, physician claims were
significantly elevated for all disease categories (p,0.001) except for
neoplasms (RR 1.02 [95% CI 0.95 to 1.09] and 0.95 [95% CI:
0.89 to 1.02] respectively, Figure 2). Risk of respiratory disease
(other than asthma) was about double, and risk of psychiatric
disorders and infectious diseases was approximately 33% to 51%
higher in individuals with asthma (p,0.001 for each disease
category).
Finally, comorbidity was 22% higher among individuals aged
65 years and older with compared to those without asthma
(p,0.001; Figure 2). Although significantly greater health services
use was seen in most disease categories, relative risks in this age
group were generally lower compared to other age groups.
Physician claim rates for respiratory disease (other than asthma)
were still higher (RR: 2.08, 95% CI [1.99 to 2.17]) in individuals
with asthma, but there was no increase rates for neoplasms,
metabolic and immunity disorders, and musculoskeletal disorders
and rates for psychiatric disorders was slightly lower (RR: 0.91,
95% CI [0.84 to 0.98]; Figure 2).
Comorbidity for conditions associated with asthma
Comorbidity, as indicated by physician claims, for several
specific conditions previously shown to be associated with asthma
was also examined (Tables 4 and 5). Among children four years
and younger, physician claim rates for most conditions were
significantly higher among those with compared to those without
asthma (Figure 3). More than 50% higher claim rates (in some
cases more than double) were seen for acute bronchitis,
pneumonia, obesity, and behavioral disorders (p,0.001 for each
disease condition). Among children aged five to 17 years,
physician claim rates for almost all conditions studied was
significantly higher among those with compared to those without
Table 4. Rates of health services claims among individuals with and without asthma for specific disease conditions, according to
age (Pediatric population).
Health Services Claims per 1000 person years
4 years and younger 5 to 17 years of age
Individuals
with asthma
Individuals without
asthma
Absolute rate
difference
Individuals
with asthma
Individuals
without asthma
Absolute rate
difference
Specific Condition
(95% confidence
interval)
(95% confidence
interval)
Pneumonia 77.4 32.1 45.3 (44.5, 46.0) 22.9 10.6 12.3 (12.1, 12.5)
Influenza 32.6 24.5 8.1 (7.6, 8.6) 20.9 15.0 5.9 (5.8, 6.1)
Upper Respiratory
Tract Infection
787.9 609.1 178.8 (176.3, 181.3) 362.5 259.3 103.2 (102.4, 104.0)
Depression 1.7 1.0 0.6 (0.5, 0.7) 30.1 21.9 8.2 (8.0, 8.4)
Anxiety disorder 40.9 26.9 13.9 (13.4, 14.5) 178.8 136.1 42.7 (42.2, 43.3)
Behavioural disorders 77.0 43.4 33.6 (32.8, 34.3) 65.0 38.9 26.1 (25.7, 26.4)
Obesity 11.7 6.2 5.5 (5.2, 5.8) 20.1 12.7 7.4 (7.2, 7.6)
Allergy 183.1 144.1 39.0 (37.8, 40.2) 120.4 91.1 29.3 (28.8, 29.7)
Acute bronchitis 179.9 101.5 78.4 (77.3, 79.6) 92.4 49.6 42.8 (42.4, 43.1)
Diabetes 7.3 5.6 1.7 (1.5, 2.0) 18.1 14.8 3.3 (3.1, 3.5)
doi:10.1371/journal.pone.0034967.t004
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e34967asthma (Figure 3). More than 50% higher claim rates were seen for
acute bronchitis, pneumonia, obesity, and depression (p,0.001 for
each disease condition).
Significantly higher physician claim rates for most conditions
were found among individuals aged 18 to 44 and 45 to 64 years
with asthma compared to those without (p,0.05 for all conditions
except lung cancer, osteoporosis and acute myocardial infarction
in 45 to 64 year olds; Figure 4). Of particular note were acute
bronchitis and pneumonia, which were at least twice as common
in those with asthma (p,0.001). Finally, with few exceptions,
comorbidity was similar in the 65 years and older age group
(Figure 4) where physician claims were twice as common for acute
bronchitis and 60% higher for pneumonia.
Sensitivity Analysis
In the unlikely scenario that individuals who were potentially
misclassified as having asthma had twice the comorbidity as those with
true asthma, misclassification could have accounted for the results seen.
In the more likely scenario that individuals who were potentially
misclassified with asthma had less comorbidity than those with true
asthma (ie. they were overdiagnosed with asthma), the relative risk of
comorbidity would be much greater than that observed [22].
Discussion
We conducted a retrospective study using universal health
administrative data to describe and quantify asthma comorbidity
in a large, complete, real world population and found asthma to be
associated with significant rates of various types of comorbidity in
individuals of different age. Specifically, compared to people
without asthma, individuals with asthma had at least 50% or more
comorbidity, as indicated by health services use, for respiratory
disease (other than asthma) in all age groups; psychiatric disorders
in individuals age four and under and age 18 to 44; perinatal
disorders in individuals 17 years and under, and metabolic and
immunity, and hematologic disorders in children four years and
under. While most of these types of asthma comorbidity have been
described before,[1,23–26] their differential impact on individuals
of different ages adjusting for a number of confounders like
socioeconomic status and other comorbidity has, to the best of our
knowledge, never been reported. These findings may be used to
guide the development of strategies to recognize and manage
asthma comorbidity throughout the lifespan to improve asthma
care.
Comorbidity may occur in patients with asthma for several
reasons and our study was not designed to determine causality.
First, asthma itself may cause or contribute to comorbidity. For
example, asthma control is often suboptimal and the consequent
physical activity limitations and disturbed sleep could contribute to
psychiatric disorders and obesity [7,27,28]. Second, therapies for
asthma may also cause or contribute to comorbidity. For example,
inhaled corticosteroids may predispose to pneumonia [29]. Third,
some comorbidity such as allergy may be linked to asthma via
common genetic and environmental factors as part of a larger
Figure 3. Adjusted relative risks and 95% confidence intervals of comorbidity, as indicated by health services use, use among
individuals 4 years and younger and 5 to 17 years with compared to without asthma for specific disease conditions. Solid diamonds
represent relative risks for individuals four years and younger; hollow diamonds represent relative risks for individuals five to 17 years. All analyses
were adjusted for age, sex, socioeconomic status, rural/urban place of residence, a co-diagnosis of COPD, and other comorbidity as indicated by ICD-
9 category.
doi:10.1371/journal.pone.0034967.g003
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severity, or likelihood of asthma. This has been well-documented
for allergic rhinitis and, more controversially, may also be true for
obesity [30,31]. Finally, it might be possible that some of the
comorbidity we observed in individuals with asthma was due to
diagnostic confusion or lack of precision.
Most of the disease associations with asthma in the current study
have been previously described; however, there were also some,
such as metabolic and immunity disorders and hematologic
disorders in children 4 years and younger, that we do not believe
have been associated with asthma before. This is most likely
because they have not been examined before and not because they
do not exist. On further examination, differences in the former
group appeared to be driven by obesity and diabetes (Table 6) and
in the later by iron deficiency anemia (Table 7). Their further
investigation would be of interest. There were also a few findings,
such as the lack of association with osteoporosis, that appeared to
contradict previous studies [1]. This could have been due to
differences in measurement of the condition between our study
and previous ones and/or differences in analysis–specifically in
potential confounding variables adjusted for. In our study we
adjusted for many variables including socioeconomic status and
other comorbidity which were not adjusted for in previous studies.
The strengths of our study were its ability to examine and
quantify all physician health services use in a large real-world,
population of individuals of various ages with and without asthma.
It also has limitations that merit emphasis. To begin, we used a
definition of asthma based on health administrative data, which
does not contain a measure of lung function so misclassification
could have occurred. This is of greatest concern in the four and
under age group because they cannot perform pulmonary function
testing making diagnosis of asthma can be very difficult. However,
misclassification would have caused the asthma and non-asthma
groups we studied to be more similar than they actually were,
which would have lessened the differences in comorbidity between
the groups and attenuated the relative risks of comorbidity we
measured. Thus any misclassification would have caused our study
to underestimate (not overestimate) the true impact of comorbidity
on individuals with asthma. This was confirmed in our sensitivity
analysis which showed that only in the extremely unlikely scenario
where those misclassified with asthma had twice the amount of
comorbidity as those with true asthma, would the increased
relative risks of comorbidity associated with asthma be negated.
Our definition of asthma was also likely to overlook milder cases
and, because it was not dependent on standardized diagnostic
criteria, may have varied in terms of who it identified. A second
limitation was that increased health services use may occur for
many reasons and our study could not distinguish increased use
due to asthma comorbidity from increased use due to other causes
such as better access to health care or learned behavior. Even
though Ontario has universal health care insurance and we
controlled for barriers to access like low socioeconomic status,
Figure 4. Adjusted relative risks and 95% confidence intervals of comorbidity, as indicated by health services use, among
individuals age 18 to 44 years, 45 to 64 years and 65 years and older with compared to without asthma for specific disease
conditions. Solid black circles represent relative risks for individuals 18 to 44 years; solid grey circles represent relative risks for individuals 45 to
64 years; hollow circles represent relative risks for individuals 65 years and older. All analyses were adjusted for age, sex, socioeconomic status, rural/
urban place of residence, a co-diagnosis of COPD, and other comorbidity as indicated by ICD-9 category.
doi:10.1371/journal.pone.0034967.g004
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have obtained prior health care access because of their asthma
might have been more likely to have found a way to overcome
these obstacles. Alternatively, using health care may partly be a
learned behavior and those who had accessed the health care
system for their asthma might have learned to use, and perhaps
overuse, health services for other conditions as well. We believe
that these factors may have accounted for a small amount of
increased health services use across all categories, but not for the
notably higher levels seen in some disease categories. Further study
investigating the reasons for increased health services use in
individuals with asthma would help to determine if they were
contributing factors. Finally, a third limitation was that physicians
in Ontario can only provide one diagnosis per claim. Therefore,
for example, if a patient presented with asthma and allergic rhinitis
(which commonly co-exist) only one would be recorded. This
might have accounted for a possible underestimate of the relative
risk of allergy in people with asthma.
In summary, we conducted a retrospective cohort study of a
large, complete, real world population and found that, compared
to people without asthma, those with asthma had notably higher
rates of many different types of comorbidity which varied
according to age. Asthma comorbidity has important implications
in terms of the evaluation and management of asthma and should
be recognized, investigated and treated appropriately. Future
investigation is needed to confirm and study the unique findings of
this study in more detail, sort out the complex interactions
between asthma and its comorbidity, and develop better
approaches to educating about and managing asthma comorbidity
in order to improve asthma care and the health of the asthma
population overall.
Table 6. Rates of the 10 most common conditions in the Endocrine, nutritional, and metabolic diseases, and immunity disorders
disease category in individuals with asthma age four years and younger and the corresponding rates in individuals without
asthma.
Health services claims per 1000 person years
Individuals with asthma Individuals without asthma
Condition (95% confidence interval) (95% confidence interval)
Obesity 8.8 (8.6, 9.1) 4.6 (4.5, 4.7)
Diabetes mellitus 7.3 (7.1, 7.5) 5.6 (5.5, 5.6)
Other metabolic disorders 6.2 (6.0, 6.4) 2.7 (2.6, 2.7)
Other endocrine disorders 4.0 (3.9, 4.2) 2.5 (2.5, 2.6)
Vitamin and other nutritional deficiencies 3.2 (3.0, 3.3) 3.0 (3.0, 3.1)
Unspecified malnutrition 2.2 (2.1, 2.4) 2.0 (2.0, 2.1)
Hypogammaglobulinemia, agammaglobulinemia, other
immunity disorders
1.9 (1.8, 2.0) 1.0 (1.0, 1.1)
Disorders of lipid metabolism 0.9 (0.8, 1.0) 0.6 (0.5, 0.6)
Acquired hypothyroidism 0.8 (0.8, 0.9) 0.7 (0.6, 0.7)
Congenital hypothyroidism 0.6 (0.5, 0.7) 0.4 (0.4, 0.4)
doi:10.1371/journal.pone.0034967.t006
Table 7. Rates of the 10 most common conditions in the Hematologic disorders disease category in individuals with asthma age
4 years and younger and the corresponding rates in individuals without asthma.
Health Services Claims per 1000 person years
Individuals with asthma Individuals without asthma
Condition (95% confidence interval) (95% confidence interval)
Iron deficiency anemia 10.5 (10.3, 10.8) 8.8 (8.7, 8.9)
Other diseases of blood, marrow, spleen 4.6 (4.4, 4.8) 3.1 (3.1, 3.2)
Hereditary hemolytic anemia 3.8 (3.7, 4.0) 1.7 (1.7, 1.7)
Purpura, thrombocytopenia, other hemorrhagic conditions 2.2 (2.1, 2.3) 1.6 (1.5, 1.6)
Neutropenia, agranulocytosis, eosinophilia 2.2 (2.0, 2.3) 1.6 (1.6, 1.7)
Coagulation defects 1.9 (1.8, 2.0) 0.8 (0.7, 0.8)
Other anemias 0.9 (0.8, 1.0) 0.9 (0.9, 0.9)
Aplastic anemia 0.6 (0.5, 0.7) 0.5 (0.5, 0.6)
Pernicious anemia 0.3 (0.3, 0.4) 0.3 (0.3, 0.3)
Acquired hemolytic anemia, excluding hemolytic disease of newborn 0.2 (0.2, 0.2) 0.1 (0.1, 0.1)
doi:10.1371/journal.pone.0034967.t007
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